PARIS Nov 17 French diagnostics company
BioMerieux (BIOX.PA) and British drugmaker GlaxoSmithKline
(GSK.L) will develop a test to help specialists determine the
most appropriate treatment for breast cancer patients.
Both companies will fund the development of the test,
BioMerieux said in a statement on Tuesday, but no financial
details of the agreement were disclosed.
Over 500,000 new cases of breast cancer are diagnosed each
year in the U.S. and Europe. Predictive tests have been shown to
improve outcomes for these patients, BioMerieux said.
Oddo Securities said in a research note the test could reach
the market as early as 2015 and that in time could yield annual
sales of 10 million to 15 million euros.
The tests can help detect the origin of tumours, which is
particularly useful in the 3 to 5 percent of patients who
receive a diagnosis after the cancer has spread and it is not
clear where it started, BioMerieux said in a statement earlier
(Reporting by Caroline Jacobs, editing by Will Waterman)